Skip to main content
SpringerLink
Log in

Antiestrogen treatment of postmenopausal women with primary high risk breast cancer

36 months of life-table analysis and steroid hormone receptor status

  • Scandinavian Breast Cancer Symposium
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Summary

The role of antiestrogen treatment in high risk postmenopausal patients with primary breast cancer is currently evaluated in a nationwide, prospective randomized trial conducted by the Danish Breast Cancer Cooperative Group. The primary treatment is total mastectomy and radiotherapy. As of February 1, 1982, 720 women were randomized to treatment with tamoxifen (30 mg daily for 1 year) and 691 women were randomized to no further therapy. Life-table analysis after 36 months shows a difference in recurrence rates of 9% (p = 0.19) in favor of the tamoxifen-treated patients. The material has been analyzed with respect to established prognostic factors such as age, degree of anaplasia, tumor size, and number of positive nodes. The rates of recurrent disease are lower in all subsets of patients treated with tamoxifen, but are only statistically significant in patients 50–59 years of age or with 4 or more positive lymph nodes. Regardless of treatment, ER negative patients have a 23% higher recurrence rate than ER positive patients after 18 months of analysis (p = 0.0033); this represents an approximate doubling of risk, and is independent of age, degree of anaplasia, tumor size, or lymph node status. With regard to PgR status, there is 11% higher recurrence rate in the PgR negative than in the PgR positive patients (p = 0.097).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Fisher B: Laboratory and clinical research in breast cancer — a personal adventure: The David A. Karnofsky memorial lecture. Cancer Res 40:3863–3874, 1980

    Google Scholar 

  2. Henderson IC, Canellos GP: Cancer of the breast. The past decade. N Engl J Med 302:17–30, 1980

    PubMed  Google Scholar 

  3. Henderson IC, Canellos GP: Cancer of the breast. The past decade. N Engl J Med 302:78–90, 1980

    PubMed  Google Scholar 

  4. Goldie JH, Bruchovsky N, Coldman AJ, Gudauskas GA: Steroid receptors in adjuvant hormonal therapy for breast cancer. Can J Surg 24:290–293, 1981

    PubMed  Google Scholar 

  5. Ingle JN, Ahmann DL, Green SJ, Edmonson JH, Bisel HF, Kvols LK, Nichols WC, Creagan ET, Hahn RG, Rubin J, Frytak S: Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. N Engl J Med 304:16–21, 1981

    PubMed  Google Scholar 

  6. Westerberg H: Tamoxifen and fluoxymesterone in advanced breast cancer: A controlled clinical trial. Cancer Treat Rep 64:117–121, 1980

    PubMed  Google Scholar 

  7. Smith IE, Harris AL, Morgan M, Ford HT, Gazet J-C, Harmer CL, White H, Parsons CA, Villardo A, Walsh G, McKinna JA: Tamoxifen versus aminoglutethimide in advanced breast carcinoma: a randomised cross-over trial. Br Med J 283:1432–1434, 1981

    Google Scholar 

  8. Palshof T, Mouridsen HT, Daehnfeldt JL: Adjuvant endocrine therapy of primary operable breast cancer. Report on the Copenhagen breast cancer trials. Eur J Cancer Suppl:183–187, 1980

  9. Hubay CA, Pearson OH, Marshall JS, Rhodes RS, DeBanne SM, Rosenblatt J, Mansour EG, Hermann RE, Jones JC, Flynn WJ, Eckert C, McGuire WL: Adjuvant chemotherapy, antiestrogen therapy and immunotherapy for stage II breast cancer: 45-month follow-up of a prospective, randomized clinical trial. Cancer 46:2805–2808, 1980

    PubMed  Google Scholar 

  10. Fisher B, Redmond C, Brown A, Wolmark N, Wittliff J, Fisher ER, Plotkin D, Bowman D, Sachs S, Wolter J, Frelick R, Desser R, LiCalzi N, Geggie P, Campbell T, Elias EG, Prager D, Koontz P, Volk H, Dimitrov N, Gardner B, Lerner H, Shibata H: Treatment of primary breast cancer with chemotherapy and tamoxifen. N Engl J Med 305:1–6, 1981

    PubMed  Google Scholar 

  11. Andersen KW, Mouridsen HT, Castberg Th, Fischerman K, Andersen J, Hou-Jensen K, Brincker H, Johansen H, Henriksen E, Rørth M, Rossing N: Organisation of the Danish adjuvant trials in breast cancer. Dan Med Bull 28:102–106, 1981

    PubMed  Google Scholar 

  12. Bloom HJG, Richardson WW: Histological grading and prognosis in breast cancer. A study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 11:359–377, 1957

    PubMed  Google Scholar 

  13. EORTC Breast Co-operative Group: Revision of standards for the assessment of hormone receptors in human breast cancer: Report of the second EORTC workshop. Eur J Cancer 16:1513–1515, 1980

    Google Scholar 

  14. Allegra JC, Lippman ME, Simon R, Thompson EB, Barlock A, Green L, Huff KK, Do HMT, Aitken SC, Warren R: Association between steroid hormone receptor status and disease-free interval in breast cancer. Cancer Treat Rep 63:1271–1277, 1979

    PubMed  Google Scholar 

  15. Osborne CK, Yochmowitz MG, Knight WA, McGuire WL: The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer 46:2884–2888, 1980

    PubMed  Google Scholar 

  16. Hähnel R, Woodings T, Vivian AB: Prognostic value of estrogen receptors in primary breast cancer. Cancer 44:671–675, 1979

    PubMed  Google Scholar 

  17. Furmanski P, Saunders DE, Brooks SC, Rich MA: The prognostic value of estrogen receptor determinations in patients with primary breast cancer: An update. Cancer 46:2794–2796, 1980

    PubMed  Google Scholar 

  18. Hilf R, Feldstein ML, Gibson SL, Savlov ED: The relative importance of estrogen receptor analysis as a prognostic factor for recurrence or response to chemotherapy in women with breast cancer. Cancer 45:1993–2000, 1980

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oncology A, The Finsen Institute, Copenhagen, Denmark

    Carsten Rose M.D. & Henning T. Mouridsen M.D.

  2. The Fibiger Laboratory, Copenhagen, Denmark

    Carsten Rose M.D. & Susan M. Thorpe Cand. Scient.

  3. Department of Clinical Physiology, The Finsen Institute, Copenhagen, Denmark

    Susan M. Thorpe Cand. Scient.

  4. Department of Pathology, Esbjerg Hospital, Copenhagen, Denmark

    Johan A. Andersen M.D.

  5. Department of Radiotherapy and Oncology, Odense Hospital, Copenhagen, Denmark

    Hans Brincker M.D.

  6. Danish Breast Cancer Cooperative Group Secretariat, The Finsen Institute, Copenhagen, Denmark

    Henning T. Mouridsen M.D. & Knud W. Andersen M.Sc.

Authors
  1. Carsten Rose M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Susan M. Thorpe Cand. Scient.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Henning T. Mouridsen M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Johan A. Andersen M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hans Brincker M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Knud W. Andersen M.Sc.
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

on behalf of the Danish Breast Cancer Cooperative Group

Additional information

sponsored by the Danish Cancer Society

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rose, C., Thorpe, S.M., Mouridsen, H.T. et al. Antiestrogen treatment of postmenopausal women with primary high risk breast cancer. Breast Cancer Res Tr 3, 77–84 (1983). https://doi.org/10.1007/BF01806237

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01806237

Keywords

Search

Navigation